For rs146381257 (ZNF106), frequencies were increased in prostate cancer (33.3%), lung cancer (28.6%), breast cancer (28.6%), lymphoid neoplasms (23.8%), urinary bladder cancer (19.0%), pancreatic cancer (14.3%), and kidney cancer (14.3%). This evidence concerns the gene ZNF106 and lung carcinoma.